Growth Metrics

Pacira BioSciences (PCRX) Non Operating Income (2016 - 2025)

Pacira BioSciences has reported Non Operating Income over the past 16 years, most recently at -$6.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$6.1 million for Q4 2025, down 157.36% from a year ago — trailing twelve months through Dec 2025 was -$8.9 million (down 144.61% YoY), and the annual figure for FY2025 was -$6.6 million, down 164.49%.
  • Non Operating Income for Q4 2025 was -$6.1 million at Pacira BioSciences, down from $3.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for PCRX hit a ceiling of $27.3 million in Q4 2022 and a floor of -$19.2 million in Q3 2022.
  • Median Non Operating Income over the past 5 years was -$289500.0 (2021), compared with a mean of -$163650.0.
  • Biggest five-year swings in Non Operating Income: tumbled 6332.48% in 2022 and later skyrocketed 4380.0% in 2024.
  • Pacira BioSciences' Non Operating Income stood at -$10.4 million in 2021, then skyrocketed by 361.88% to $27.3 million in 2022, then fell by 3.37% to $26.3 million in 2023, then tumbled by 59.81% to $10.6 million in 2024, then plummeted by 157.36% to -$6.1 million in 2025.
  • The last three reported values for Non Operating Income were -$6.1 million (Q4 2025), $3.2 million (Q3 2025), and -$10.4 million (Q2 2025) per Business Quant data.